Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 125

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 125
---
 logistics facilities in approximately 70 countries around the world. Our office premises house all of our support functions, plus operational representatives from our subsidiaries and the Company. A breakdown of our sites by use and by ownership status (owned versus leasehold) is provided below. This breakdown is based on surface area. All surface area figures are unaudited.

| Breakdown of sites by use |     |     | Breakdown of sites by ownership status |     |
| Industrial                | 59% |     | Leasehold                              | 26% |
| Research                  | 13% |     | Owned                                  | 74% |
| Offices                   | 13% |     |                                        |     |
| Logistics                 | 9%  |     |                                        |     |
| Other                     | 6%  |     |                                        |     |

D.2. Description of our sites Sanofi industrial sites As part of the process of transforming Sanofi and creating Global Business Units, we are continuing to adapt the organization of the Manufacturing & Supply department in support of our new business model. The Manufacturing & Supply department focuses on customer needs and service quality; the sharing of “Sanofi Manufacturing System” good manufacturing practices; and the development of a common culture committed to quality. The organizational structure of Manufacturing & Supply is aligned on our corporate structure and our four Global Business Units: Specialty Care, General Medicines, Vaccines and Opella, which is now part of Sanofi’s discontinued operations (see “Item 5. Operating and Financial Review and Prospects — A.1.1. 2024 Overview”). The Manufacturing & Supply department is also responsible for Sanofi Global HSE and Global Supply Chain. At the end of 2024 , we were carrying out industrial production at 52 sites in 24 countries: • 8 sites for our Specialty Care operations; • 21 sites for our General Medicines operations; • 9 sites for the industrial operations of Vaccines; and • 13 sites for our Opella operations, which are now part of Sanofi’s discontinued operations (see “Item 5. Operating and Financial Review and Prospects — A.1.1. 2024 Overview”). The quantity of units sold in 2024 , including in-house and outsourced production, was 4.2 billion. This comprised: • Biopharma: 2.1 billion units; and • Opella: 2.1 billion units. We believe that our production facilities are in compliance with all material regulatory requirements